Long-Term Outcomes of ABO-Incompatible Versus Compatible Living Donor Liver Transplantation

NCT ID: NCT07105085

Last Updated: 2025-08-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

511 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-01

Study Completion Date

2025-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This retrospective cohort study investigates the long-term outcomes of ABO-incompatible (ABO-I) versus ABO-compatible (ABO-C) living donor liver transplantation (LDLT). A total of 511 patients at a single high-volume transplant center in Korea.

The study aims to compare overall survival and the incidence of biliary complications.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This retrospective cohort study investigates the long-term outcomes of ABO-incompatible (ABO-I) versus ABO-compatible (ABO-C) living donor liver transplantation (LDLT). A total of 511 patients underwent LDLT between January 2012 and December 2022 at a single high-volume transplant center in Korea. Among them, 121 received ABO-I grafts using a rituximab-based desensitization protocol, while 390 underwent ABO-C LDLT. The study aims to compare overall survival and the incidence of biliary complications, as well as to identify risk factors specific to each group. This analysis provides insights into the long-term safety and efficacy of ABO-I LDLT in regions with low deceased donor organ availability.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Transplantation Liver Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

living donor liver transplantation

other intervention cannot be applied.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All adult patients who underwent LDLT at the study center from 2012 to 2022

Exclusion Criteria

* Pediatric patients, deceased donor recipients, multi-organ transplants.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Seoung Hoon Kim

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Seoung Hoon Kim

National Cancer Center, Korea

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Seoung Hoon kim, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

National Cancer Center

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCC2023-0110

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.